Skip to main content

Advertisement

Table 3 Mechanisms of action of drugs currently in Phase 1, Phase 2, and Phase 3 clinical trials (as of February 27, 2014)

From: Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

Unique compounds per MoA (current pipeline 02–27) Phase 1 Phase 2 Phase 3 Total
Symptomatic for cognition 5 10 10 25
Symptomatic for behavior 2 3 4 9
Disease-modifying small molecule (amyloid-related) 4 5 1 10
Disease-modifying small molecule (tau-related) 3 0 1 4
Disease-modifying small molecule (neuroprotector) 2 19 4 25
Disease-modifying immunotherapy 4 8 3 15
Therapeutic device 2 4 0 6
Stem cells 0 1 0 1
Total 22 50 23 95